2-AMINO-7-(1-SUBSTITUTED-2-HYDROXYETHYL)-3,5-DIHYDRO-PYRROLO[3,2-D]PYRIMIDIN-4-ONES

Abstract: The invention relates to the 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo[3,2-d]pyr imidine-4-ones of formula (I), and tautomers thereof, wherein Ar represents biaryl, carbocyclic or heterocyclic aryl; pharmaceutically acceptable prodrug ester derivatives; and pharmaceutically acceptable salts thereof, which are particularly useful as potent purine nucleoside phosphorylase (PNP) inhibitors.

Description: 2-AMINO-7-(1-SUBSTITUTED-2-HYDROXYETHYL)-3.5-DIHYDRO- PYRROLOr3.2-DlPYRIMIDIN-4-ONES The invention relates to 9-deazaguanine derivatives, namely 2-amino-7-(1 - substituted-2-hydroxyethyi)-3,5-dihydro-pyrrolo[3,2-d] pyrimidin-4-ones which are particularly potent purine nucleoside phosphorylase (PNP) inhibitors, and to the pharmaceutical use thereof to treat conditions in mammals which are responsive to purine nucleoside phosphorylase inhibition. 7-(1 -Substituted-hydroxyalkyl)-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-ones, including specific 7-(1 -aryl-3-hydroxypropyl)-substituted compounds, are inter alia, disclosed in International patent applications nos. WO 91/06548 and WO 93/21 187. However, there is no suggestion to prepare the novel 7-(1 -substituted-2-hydroxyethyl)- substituted compounds of the present invention to obtain unexpectedly potent PNP inhibitors. The invention relates to the compounds of formula I Ar-CH-CH 2 OH and tautomers thereof, wherein Ar represents biaryl, carbocyclic or heterocyclic aryl; pharmaceutically acceptable prodrug ester derivatives; and pharmaceutically acceptable salts thereof. The compounds of the invention possess an asymmetric carbon atom and therefore exist as racemates and the (R) and (S) enantiomers thereof. The present invention is intended to include these forms, also diastereoisomers and mixtures thereof if two or more asymmetric centers are present. Preferred are the enantiomers of formula la and tautomers thereof, wherein Ar represents biaryl, carbocyclic aryl or heterocyclic aryl; pharmaceutically acceptable prodrug ester derivatives thereof; and pharmaceutically acceptable salts thereof. Embodiments of the invention are said compounds of formula I and la wherein Ar represents monocyclic carbocylic aryl or monocyclic heterocyclic aryl. A particular embodiment of the invention relates to the compounds of Formula I or la wherein Ar is phenyl or phenyl substituted by one to five substituents, preferably by one or two substituents. Preferred are the compounds of formula II and the corresponding enantiomers of formula lla and tautomers thereof, wherein R- and R 2 represent independently hydrogen, halo, lower alky!, hydroxy, lower alkoxy, aryl-lower alkoxy, acyloxy, aryloxy, trifluoromethyl, cyano, (hydroxy, lower alkoxy or acyloxy)-lower alkyl, or (lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl)-lower alkyl; or Ri and R 2 together on adjacent carbon atoms represent lower alkylenedioxy; prodrug pharmaceutically acceptable ester derivatives thereof; and pharmaceutically acceptable salts thereof. A further embodiment of the invention relates to the compounds of formula I and la wherein Ar is monocyclic heterocyclic aryl comprising thienyl, furanyl, pyridyl, pyrrolyl, thiazolyl, pyrazinyl, pyridazinyl or pyrazolyl. Preferred are the compounds of formulae I and la and tautomers thereof, wherein Ar is phenyl, pyridyl or halophenyl such as chloro- or fluorophenyl; pharmaceutically acceptable carboxylic acid derived prodrug ester derivatives thereof; and pharmaceutically acceptable salts thereof. Particularly preferred are the enantiomers of formula 111 and tautomers thereof, wherein R represents hydrogen, chloro, or fluoro; pharmaceutically acceptable prodrug esters thereof; and pharmaceutically acceptable salts thereof. Preferred in turn are the compounds of formula III wherein R is hydrogen or fluoro at the ortho position. Further preferred embodiments of the invention relate to the specific compounds disclosed in the examples. The general definitions used herein have the following meaning within the scope of the present invention. Aryl represents carbocyclic or heterocyclic aryl, either monocyclic or bicyclic. Monocyclic carbocyclic aryl represents optionally substituted phenyl, being preferably phenyl or phenyl substituted by one to three substituents, such being advantageously lower alkyl, hydroxy, lower alkoxy, acyloxy, halogen, cyano, trifluoromethyl, carbocyclic aryloxy or carbocyclic aryl-lower alkoxy. Bicyclic carbocyclic aryl represents 1- or 2-naphthyl or 1- or 2-naphthyl substituted by, e.g., lower alkyl, lower alkoxy or halogen. Monocyclic heterocyclic aryl represents optionally substitued thienyl, furanyl, pyridyl, pyrrolyl, thiazolyl, pyrazinyl, pyridazinyl or pyrazolyl preferably optionally substituted thiazolyl, thienyl, furanyl or pyridyl. Optionally substituted furanyl represents 2- or 3-furanyl preferably substituted by lower alkyl. Optionally substituted pyridyl represents 2-, 3- or 4-pyridyl or 2-, 3- or 4-pyridyl preferably substituted by lower alkyl, halogen or cyano. Optionally substituted thienyl represents 2- or 3-thienyl or 2- or 3-thienyl preferably substituted by lower alkyl. Optionally substituted thiazolyl represents, e.g., 4-thiazolyl, or 4- thiazolyl substituted by lower alkyl. Bicyclic heterocyclic aryl represents preferably indolyl or benzothiazolyl optionally substituted by hydroxy, lower alkyl, lower alkoxy or halogen, advantageously 3-indolyl or 2-benzothiazolyl. Aryl as in aryl-lower alkyl is preferably phenyl or phenyl substituted by one or two of lower alkyl, lower alkoxy, hydroxy, lower alkanoyloxy, halogen, trifluoromethyl or cyano; also, optionally substituted naphthyl. Aryl-lower alkyl is advantageously benzyl or 1- or 2-phenethyl optionally substituted on phenyl by one or two of lower alkyl, lower alkoxy, hydroxy, lower alkanoyloxy, halogen, cyano or trifluoromethyl. Biaryl represents phenyl substituted by carbocyclic aryl or heterocyclic aryl as defined herein, ortho, meta or para to the point of attachment of the phenyl ring, advantageously para, such as 4-biphenyl. The term "lower" referred to herein in connection with organic radicals or compounds respectively defines such with up to and including 7, preferably up and including 4 and advantageously one or two carbon atoms. Such may be straight chain or branched. A lower alkyl group preferably contains 1 -4 carbon atoms and represents for example, ethyl, propyl, butyl or advantageously methyl. A lower alkoxy group preferably contains 1-4 carbon atoms and represents for example, methoxy, propoxy, isoproproxy or advantageously ethoxy. Halogen (halo) preferably represents fluoro or chloro, but may also be bromo or iodo. Acyl is derived from a carboxylic acid and represents preferably optionally substituted lower alkanoyl, carbocyclic aryl-lower alkanoyl, aroyl, lower alkoxycarbonyl or aryl-lower alkoxycarbonyl, advantageously optionally substituted lower alkanoyl, or aroyl. Lower alkanoyl is preferably acetyl, propionyl, butyryl, or pivaloyl. Optionally substituted lower alkanoyl for example represents lower alkanoyl or lower alkanoyl substituted by lower alkoxycarbonyl, lower alkanoyloxy, lower alkanoylthio, lower alkoxy, or by lower alkylthio. Aroyl is preferably monocyclic carbocyclic or monocyclic heterocyclic aroyl. Monocyclic carbocyclic aroyl is preferably benzoyl or benzoyl substituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl. Monocyclic heterocyclic aroyl is preferably pyridylcarbonyl or thienylcarbonyl. Acyloxy is preferably optionally substituted lower alkanoyloxy, lower alkoxycarbonyloxy, monocyclic carbocyclic aroyloxy or monocyclic heterocyclic aroyloxy. Aryl-lower alkoxycarbonyl is preferably monocyclic carbocyclic-lower alkoxycarbonyl, advantageously benzyioxycarbonyl. The compounds of Formulae I, la, II, lla and III are hereinafter referred to as the compounds of the invention and as such include the tautomers, pharmaceutically acceptable esters and pharmaceutically acceptable salts thereof, e.g. as defined below. The compounds of the invention represent 9-substituted-9-deazaguanines which are named herein as 7-substituted 2-amino-3,5-dihydro-4H-pyrrolo[3,2- d]pyrimidin-4-ones, and as such can exist in several tautomeric forms, e.g., as represented by structure IV. and other structures involving allowable rearrangement of positions of double bonds. All tautomeric forms of the compounds of the invention are included within the scope of the invention. The compounds of the invention may also exist in the form of pharmaceutically acceptable esters, and as such are included within the scope of the invention. Pharmaceutically acceptable esters are preferably prodrug ester derivatives, such being convertible by solvolysis or under physiological conditions to the free alcohols of formula I. Pharmaceutically acceptable prodrug esters of the alcohols of the invention are those derived from a carboxylic acid, a carbonic acid monoester or a carbamic acid, advantageously esters derived from an optionally substituted lower alkanoic acid or an arylcarboxylic acid. The esters are represented by formula lb Ar-CH-CH 2 -OR' in which R' represents acyl as defined herein. Such are convertible in vivo to the compounds of formula 1. The compounds of the invention may also exist in the form of pharmaceutically acceptable salts, and as such are included within the scope of the invention. Pharmaceutically acceptable salts represent acid addition salts with conventional acids, for example, mineral acids, e.g., hydrochloric acid, sulfuric or phosphoric acid, or organic acids, for example, aliphatic or aromatic carboxylic or sulfonic acids, e.g., acetic, propionic, succinic, glycolic, lactic, malic, tartaric, citric, ascorbic, maleic, fumaric, hydroxymaleic, pyruvic, pamoic, methanesulfonic, toluenesulfonic, naphthalenesulfonic, sulfanilic or cyclohexylsulfamic acid; also amino acids, such as arginine and lysine. For compounds of the invention having acidic groups, for example, a free carboxy group, pharmaceutically acceptable salts also represent metal or ammonium salts, such as alkali metal or alkaline earth metal salts, e.g., sodium, potassium, magnesium or calcium salts, as well as ammonium salts, which are formed with ammonia or suitable organic amines. The compounds of the invention are particularly useful in mammals as purine nucleoside phosphorylase (PNP) inhibitors, e.g. for selectively suppressing T-cell mediated immunity in mammals, and for treating conditions in mammals in which T-cells are involved, such as autoimmune diseases, transplant rejection or psoriasis. Disorders considered to be of autoimmune origin include rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis, type I diabetes, multiple sclerosis, psoriasis and certain forms of dermatitis, Crohn's disease, uveitis, asthma and the like. The compounds of the invention are also useful for the treatment of gout. The compounds of the invention are useful for inhibiting transplant rejection, e.g. for the treatment of transplant recipients (e.g., in heart, lung, combined heart-lung, liver, heart, kidney, pancreas, skin or corneal transplants), including both allo- and xeno-transplant rejection. The compounds of the invention are also indicated for the prevention of graft-versus-host disease, such as following bone marrow transplantation. For such indications the compounds of the invention may be used alone or in combination with known immunosuppressive agents. Such immunosuppressive agents include cyclosporine, tacrolimus, mycophenolic acid (mycophenolate mofetil), brequinar (brequinar sodium), rapamycin and the like. The dose of these agents required to achieve an immunosuppressive dose when used in combination may be lower, thus reducing the incidence of undesirable side effects associated with the particular known immunosuppressive agent, e.g., nephrotoxicity. The compounds of the invention are also useful for inhibiting the in vivo metabolic degradation of purine nucieosides via phosphorolysis, and are thus, useful to potentiate the antiviral and antitumor efficacy of 2' and/or 3'-mono- or dideoxypurine nucieosides. For instance, they are useful for potentiating e.g., 2', 3'- dideoxyadenosine, 2', 3'-dideoxyguanosine or 2', 3'-dideoxyinosine for the treatment of retrovirus infections such as acquired immunodeficiency syndrome (AIDS). They are also useful for potentiating the antitumor/cytotoxic effect of e.g., 2'-deoxyguanosine in mammals. The above-cited properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., rats, mice, dogs, monkeys, and isolated cells thereof. Said compounds can be applied in vitro in the form of solutions, e.g., preferably aqueous solutions and in vivo either enterally or parenterally, advantageously orally and intravenously. The dosage in vitro may range between about 10 "5 and 10 "9 molar concentrations. The dosage in vivo may range, depending on the route of administration, between about 1 and 100 g/kg. PNP inhibition can be measured by measuring the formation of [ 1 ' C]-inosine [Biomedicine, 33, 39 (1980)] using calf spleen as the enzyme source and 1 or 50 mM phosphate. Results are expressed as IC50 values, corresponding to the concentration of compound required to achieve a 50% reduction of the formation of hypoxanthine. PNP inhibition can also be determined in vitro using an enzymic method for the determination of inorganic phosphate (see Chem. Pharm. Bull., 1981 , 29:1451-5), based on the principle of forming hydrogen peroxide with purine nucleoside phosphorylase (PNP) and xanthine oxidase, to colorimetrically measure the degree of linkage between enzyme and substrate (inosine). Calf spleen PNP is used as the enzyme source. The IC 50 values for the compounds studied are determined graphically at two phosphate concentrations (1 and 50 mM) from a plot of percent inhibition versus compound concentration. Representative compounds of the invention typically have IC 50 s of about 20 nM at 1 mM phosphate concentration in this assay. The selective suppression of spontaneous T-cell proliferation in vitro is measured by the potentiation of the cell growth inhibitory activity (cytotoxicity) of 2'- deoxyguanosine (d-Guo) by the compounds of the invention, determined as follows: Human CCRF-CEM cells are grown in RPMI-1640 medium. To suspension cultures of these cells, d-Guo at a fixed concentration (10μM) and the candidate PNP inhibitor at varied concentrations are added and the number of cells are determined in a Coulter counter 24, 48, and 72 hours thereafter. From these data, the IC 50 is calculated as the concentration of PNP inhibitor required to reduce the increase in cell number between 0 and 72 hours to 50% of that of control cultures. This method is similar to that previously used to determine the effectiveness of PNP inhibitors on potentiation of the toxicity of d-Guo. [See D. A. Shewach et al., Cancer Res., 46, 519 (1986); J. C. Sircar et al., Agents and Actions, 21 , 253 (1987), also Methods in Pharmacology, D. M. Paten, ed. 1985, pp. 147-162]. Representative compounds of the invention typically have IC 50 s of about 100 nM in the CCRF- CEM cell assay. PNP inhibition of the compounds of the invention can also be determined in vivo by demonstrating an increased level of the nucleoside mosine in mice (see Ann NY Acad. Sci., 1985, 451 :313-4) when compared to vehicle treated mice. Representative compounds of the invention typically cause a significant increase in the plasma levels of mosine at a dose of, e.g. about 10 mg/Kg p.o. The immunosuppressive activity can also be determined in further animal models of T-cell mediated immune responses such as experimental allergic encephalomyelitis, Freund's adjuvant or collagen-induced arthritis, and models of graft vs. host reactions Protection against transplant rejection can be determined in a mouse tail skin transplantation procedure. For instance, mice are anesthetized with tnbromoethanol i p injection according to the method of Papaioannou and Fox (Lab. Animal Science 1993;43:189-92). The mouse tail skin transplant rejection model is a modification of that described by Baily and Usama (Transpl. Bull. 1960;7:424-5). Four skin grafts per mouse are exchanged between strains [C57BIJ10-SnJ (H-2K b ) and B10.BR/SgSnJ(H- 2K k )] at surgery (dO). Fitted skin grafts are made with a scalpel, and tail graft sites are protected with tubing for 2 days following surgery. Mouse tails are evaluated at day 7 for missing grafts. Only those graft sites that have patent grafts at day 7 are evaluated at later scoring intervals. Grafts are scored numerically for signs of rejection at -weekly scoring intervals starting day 14. Dose-group mean graft scores are compared statistically. Drug treatment is considered efficacious if graft scores of compound treated mice are significantly lower than those of vehicle treated mice at days 20/21 and 27/28. Representative compounds of the invention are effective in protecting against transplant rejection at a dose of about 50 mg/Kg/day in the mouse. Further a combination of a typical compound of the invention and cyclosporin is superior to either cyclosporin or the PNP inhibitor alone in the transplant rejection model, thus leading to a reduction of the dose of cyclosporin and of the side effects associated therewith. Thus, the compounds of the invention have an immunosuppressant-sparing effect when administered in combination, e.g., a cyclosporin-sparing effect. The compounds of the invention can be prepared by adaptation of previously reported synthetic methodology, e.g., M. I. Lim, R. S. Klein, and J. J. Fox, J. Org. Chem., 44, 3826 (1979); M. I. Lim., R. S. Klein, and J. J. Fox, Tetrahedron Lett., 21 , 1013 (1980); M. I. Lim and R. S. Klein, Tetrahedron Lett., 22, 25 (1981 ); M. I. Lim. W. Y. Ren, B. A. Otter, and R. S. Klein, J. Org. Chem., 48, 780 (1983), as described below and illustrated in the examples. Said compounds of the invention are prepared by treating a compound of the formula wherein Ar has meaning as previously defined, R 3 represents lower alkyl, R 4 represents carbocyclic aryl, R 5 represents lower alkyl, and R 6 represents an O-protecting group, with anhydrous ammonia; and if required converting a resulting compound of formula I into another compound of the invention. Lower alkyl as defined for R 3 and R 5 represents C C 7 -alkyl, advantageously methyl or ethyl. Carbocyclic aryl as defined for R 4 represents advantageously phenyl. An O-protecting group as defined for R 6 represents, e.g., tetrahydropyranyl, benzyl, trityl and the like. The condensation of an intermediate of formula V with ammonia and cyclization to a compound of the invention, e.g., of formula I, II or III is preferably carried out in a polar inert non-aqueous solvent such as a lower aliphatic alcohol, advantageously methanol, preferably at elevated temperature, e.g., 80-100°C under pressure in a closed vessel. The starting materials of the formula V are advantageously prepared by first treating a pyrrole derivative of the formula VI wherein Ar, R 3 and R 6 have meaning as defined herein, and R 7 represents hydrogen or lower alkoxycarbonyl, with a carbocyclic aroyl isothiocyanate, advantageously benzoyl isothiocyanate, in an inert solvent such as dichloromethane to yield a compound of the formula VII wherein Ar, R 3 , R 4 , R 6 and R 7 have meaning as defined above. Subsequent condensation of intermediates of formula VII with a reactive derivative of a lower alkylcarbinol, e.g., a lower alkyl haiide, advantageously methyl iodide, in an inert solvent such as methylene chloride, in the presence of an organic or inorganic base, e.g., an amine such as 1 ,5-diazabicyclo [4.3.0]non-5-ene (DBN) yields intermediates of formula V. The pyrrole starting materials of formula VI can be prepared similarly to methodology described in the art for the synthesis of 3-amino-4-substituted-2- pyrrolecarboxylic acids and esters thereof, e.g., as described in J. Org. Chem. 44, 3826 (1979), and as particularly illustrated herein. Said pyrrole compounds are advantageously prepared as illustrated below for compounds of formula VI wherein R 3 represents methyl. (XI) (X) (XII) Na j CO j (XIII) Ar in the above compounds has meaning as previously defined herein. In summary, the 3-substituted-3-arylpropionitrile VIII is condensed with ethyl formate in the presence of e.g. sodium hydride in anhydrous tetrahydrofuran to yield the corresponding 2-formyl-3-arylpropionitrile IX which is in turn condensed with glycine methyl ester in the presence of e.g. sodium acetate to yield the enamine of formula X. The enamine of formula X is in turn N-protected with ethyl chloroformate and the resulting N-ethoxycarbonyl derivative XI is cyclized in the presence of a base, e.g., DBN or K 2 C0 3 , to yield the N-protected pyrrole of formula XII. The intermediate of formula XI is formed in situ and usually not isolated. Deprotection by treatment with e.g. sodium carbonate in methanol yields the starting material of formula VI wherein R 7 represents hydrogen. The β-hydroxymethyl-β-arylpropionitriles of formula VIII (R 6 being H) are either known in the art or are prepared according to methodology known in the art, and are then O-protected using methods well-known in the art. Such are typically prepared by condensing the appropriate aryiacetic acid ester with, for example, bromoacetonitrile in the presence of a strong base, e.g., lithium diethylamide to obtain the corresponding β-(lower alkoxycarbonyl)-β-arylpropionitrile which is selectively reduced to the corresponding β-(hydroxymethyl)-β-arylpropionitrile with a reducing agent suitable for the selective reduction of an ester, such as lithium or sodium borohydride. The optically active β-hydroxymethyl-β-arylpropionitriles can be advantageously prepared as follows: The appropriate aryiacetic acid, preferably in form of an acid chloride is condensed with the appropriate optically active (R)-4-monosubstituted-2-oxazolidinone (e.g. 4(R)-phenyl-2-oxazolidinone) in the presence of a strong base, such as n-butyl lithium under conditions well-known in the art to obtain the corresponding enantiomer, 3-(arylacetyl)-4-(R)-substituted-2-oxazolidinone. This is in turn condensed with bromoacetonitrile in the presence of, e.g., hexamethyldisilamide to give the corresponding optically active 3-(β-cyano-α-arylpropionyl)-4-(R)-substituted-2- oxazolidinone which is reduced with lithium borohydride to give the corresponding enantiomer of an alcohol of formula VIII wherein R 6 is hydrogen, namely of β- (hydroxymethyl)-β-arylpropionitrile. The other enantiomer is similarly prepared. Alternatively, the compounds of formula I are prepared by condensing an intermediate of formula VI with cyanamide, optionally in a polar solvent such as isopropanol, at elevated temperature such as about 100-150°C, in the presence of acid, e.g., concentrated hydrochloric acid, followed by removal of the O-protecting group. The invention also relates to any novel starting materials and processes for their manufacture. Any mixtures of final products or intermediates obtained can be separated on the basis of the physico-chemical differences of the constituents, in known manner, into the pure final products or intermediates, for example by chromatography, distillation, fractional crystallization, or by formation of a salt if appropriate or possible under the circumstances. The compounds of the invention or intermediates can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. The invention further relates to pharmaceutical compositions suitable for ente«al, such as oral or rectal, transdermal and parenteral administration to mammals including man, which are useful to inhibit purine nucleoside phosphorylase activity and for the treatment of disorders responsive thereto, comprising an effective amount of a pharmacologically active compound of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers. Preferred pharmaceutical compositions are tablets and gelatin capsules comprising the active ingredient together with a) diluents, b) lubricants; for tablets also c) binders; if desired d) disintegrants; and/or e) absorbents, colorants, flavors and sweeteners; and other components as desired, all including those know and used in the art. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50% of the active ingredient. Suitable formulations for transdermal application include an effective amount of a compound of the invention with carrier, and advantageously may be in the form of a device such as a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin. The invention further relates to a method (i) of inhibiting purine nucleoside phosphorylase activity in mammals and treating diseases and conditions responsive thereto, e.g. autoimmune disorders, rejection of transplantation, or psoriasis; (ii) of selectively suppressing T-cell function and cellular immunity in mammals; (iii) of inhibiting the phosphorolysis and metabolic breakdown of antiviral or antitumor purine nucieosides in mammals; or (iv) of potentiating the antiviral or antitumor effect of 2' or 3'-monodeoxypurine nucieosides or of 2', 3'-dideoxypurine nucieosides in mammals, which comprises administering to a mammal in need thereof an effective inhibiting amount of a compound of the invention or of a pharmaceutical composition comprising a said compound in combination with one or more pharmaceutically acceptable carriers (if appropriate in conjunction with the purine nucleoside, either separately or in combination therewith). The pharmaceutically acceptable effective dosage of active compound of the invention to be administered is dependent on the species of warm-blooded animal (mammal), the body weight, age and individual condition, and on the form of administration. A unit dosage for a mammal of about 50 to 70 kg may contain between about 1 and 150 mg of the active ingredient. The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees Centigrade. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 and 100 mm Hg. The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g. microanalysis and spectroscopic characteristics (such as MS, IR, NMR and UV). Depending on the chemical nature of the substituent at the asymmetric carbon, an enantiomer having the configuration depicted in formula la, lla or III, is according to conventional rules of nomenclature, named (R) or (S). If such enantiomer is (R), then the corresponding antipode would be called (S). Example 1 To a solution of 2-amino-7-[1 -(2-fluorophenyl)-2(R)-[(tetrahydropyran-2-yl)oxy]ethyl]-3,5- dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one (30 g, 0.08 mol) in MeOH (500 mL) is added 2N HCI (50 mL). The reaction mixture is stirred at ambient temperature for - 3 hours. The resulting solution is neutralized with saturated NaHCU3 solution (100 mL) and H2O (500 mL) is added after which the mixture is stirred for 30 minutes. The white solid which precipitates is then collected and washed with H2O (2 X 20 mL) and E1.2O (2 X 20 mL) to provide 2-amino-7-[1 -(2- fluorophenyl)-2(R)-hydroxyethyl]-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one, m.p. 263-264°C, of the formula The starting material is prepared as follows: To a solution of 2-fluorophenylacetic acid (450 g, 3.0 mol) in CH2CI2 (900 mL) is added SOCI2 (714 g, 6 mol) dropwise. After addition is complete, the reaction mixture is heated to reflux for 2 hours. Subsequently, the solvent is removed in vacua after which vacuum distillation of the resulting oil provides 2-fluorobenzeneacetyl chloride. To a -78°C solution of 4(R)-phenyl-2-oxazolidinone (340 g, 2.08 mol) in THF ( 8000 mL), is added n-BuLi (2.5 M, 920 mL, 1 .1 eq). The reaction mixture is stirred for 20 minutes and 2- fluorobenzeneacetyl chloride (358 g, 2.08 mol) is added. After 2 hours the reaction mixture is quenched with saturated NH4CI solution (1 X 1000 mL). The organic layer is separated, washed with H2O (1 X 1000 mL), saturated NaCl solution ( 2 X 1000 mL) and then concentrated in vacuo. This procedure yields 3-[(2-fluorophenyl)-acetyl]-4(R)-phenyl-2- oxazolidinone. To a solution of 3-[(2-fluorophenyl)-acetyl]-4(R)-phenyl-2-oxazolidinone (435 g, 1.45 mol) in THF (6000 mL), is added sodium hexamethyldisilamide [(TMS) 2 NNa, 1 M in THF, 1480 ml, 1.48 mol] dropwise at -78°C The resulting mixture is then warmed to -30°C and stirred for 2.5 hours. After this time the reaction mixture is recooled to -78°C and a solution of BrCH2CN (175 g, 1.46 mmol) in THF (200 mL) is added. The reaction mixture is then warmed to -40°C and stirred for 2 hours. Subsequently the resulting solution is treated with saturated NH4CI (1 X 3000 ml) and extracted with EtOAc (1 X 3000 mL). The organic layer is separated, washed with H O (1 X 1500 mL), saturated NaCl solution ( 2 X 1500 mL), dried over MgS0 and concentrated in vacuo, to provide 3-[(R)-β-cyano-α-(2-fluorophenyl)-propionyl]-4-(R)-phenyl-2- oxazolidinone, m.p. 179-181 °C. 3-[(R)-β-Cyano-α-(2-fluorophenyl)-propionyl]-4-(R)-phenyl-2-oxazolidinone (400 g, 1.18 mol) is suspended in THF (4000 mL) and H2O (25 mL). The reaction mixture is cooled in ice bath to 0°C and a solution of LiBH in THF (2M, 887 ml, 1.77 mol, 1.5 eq) is added slowly. The mixture is then stirred at 0°C for 2 hours, after which 2N HCI (1500 mL) is cautiously added. The resulting solution is then extracted with Et2θ ( 2 X 1500 mL). The combined organic phases are then washed with saturated NaCl solution ( 2 X 1500 mL), dried over MgSU4 and concentrated in vacuo. The solid 4(R)-phenyl-2-oxazolidinone is recovered by filtration and washed with Et2θ ( 2 X 100 mL). The filtrate is then chromatographed (silica gel, EtOAc/Hexanes, 1 :3 ) to give β(R)-(hydroxymethyl)-β-(2-fluorophenyl)-propionitrile as an oil. To a solution of β(R)-(hydroxymethyl)-β-(2-fluorophenyl)-propionitrile (210 g, 1.18 mol) in Et2θ (200 ml), is added 3,4-dihydro-2H-pyran (225 ml, 2.68 mol) at ambient temperature. The mixture is stirred for 5 minutes and POCI3 (5 mL) is added dropwise. The reaction mixture is stirred for 30 minutes at ambient temperature and then refluxed for 2 hours. The resulting solution is allowed to cool and the solvent is removed in vacuo. The residue is then chromatographed (EtOAc/hexane, 1 :4) to give β(R)-[[(tetrahydropyran-2-yl)oxy]methyl]-β-(2- fluorophenyl)-propionitrile as an oil. To a 0°C solution of β(R)-[[(tetrahydropyran-2-yl)oxy]methyl]-β-(2-fluorophenyl)propionitrile (240 g, 0.91 mol) in Et 0 (3000 mL) and hexane (3000 mL), is added NaH (60%, 127g, 3.2 mol, 3.5 eq) and the resulting mixture is stirred for 30 minutes. Ethyl formate (540g, 7.3 mol. 8 eq) is added and the reaction mixture is stirred at 0°C for 1 hour. The cooling bath is removed and the mixture is stirred at ambient temperature for two days. After this time water (3000 mL) is added and the aqueous phase is washed with hexane ( 2 X 1000 mL), after which the pH is adjusted to between 6-7 with 1 N HCI. Subsequently the aqueous phase is extracted with Et2θ (5 X 400 mL) and the combined organics washed with brine (2 X 2000 mL), dried over MgSC>4 and concentrated in vacuo. This provides α-(hydroxymethylidenyl)-β(R)-[(tetrahydropyran-2- yloxy)methyl]-β-(2-fluorophenyl)-propionitriie which is used without purification for the next reaction. To a solution of α-(hydroxymethylidenyl)-β(R)-[(tetrahydropyran-2-yl-oxy)- methyl]-β-(2- fluorophenyl)-propionitrile (261 g, 0.90 mol) in MeOH (4000 mL) and H2O (700 mL), is added glycine methyl ester hydrochloride (226g, 1.80 mol, 2 eq) and NaOAc (185g, 2.25 mol, 2.5 eq). The reaction mixture is stirred at ambient temperature for 2 hours, and then the solvent is removed in vacuo. The resulting material is then dissolved in EtOAc (2 X 1000 mL). The ethyl acetate solution is then washed with H2O (1 X 1000 mL), saturated NaCl solution (2 X 1000 mL) and dried over MgSθ4. Subsequently, the solvent is removed in vacuo to give α-[[(carbomethoxymethyl)-amino]methylidenyl]-β(R)-[(tetrahydropyran-2-yloxy)- methyl]-β-(2-fluorophenyl)-propionitrile. To a 0°C solution of α-[[(carbomethoxymethyl)amino]methylidenyl]-β(R)-[(tetrahydropyran-2- yloxy)methyl]-β-(2-fluorophenyl)-propionitrile (320 g, 0.88 mol) in CH2CI2 (1500 mL), is added a solution of DBU (305.8 g, 2.46 mol, 2.8 eq) in CH2CI2 (500 mL). Subsequently a solution of ethyl chloroformate (219 g, 2.02 mol, 2.3 eq) in CH2CI2 (500 mL) is slowly added. The reaction mixture is allowed to warm to ambient temperature and is stirred for -12 hr. Water (2000mL) is added and the aqueous phase extracted with CH2CI2 (1 X 1000 mL). The organic layer is washed with H2O (1 X 2000mL), saturated NaCl solution (2 X 2000mL) and dried over MgSθ4. The solvent is then removed in vacuo to provide ethyl methyl 3-amino-4-[1-(2- fluorophenyl)-2(R)-[(tetrahydropyran-2-yloxy)ethyl]-1 H-pyrrole-1 ,2-dicarboxylate as an oil. A suspension of ethyl methyl 3-amino-4-[1 -(2-fluorophenyl)-2(R)-[(tetrahydropyran-2- yloxy)ethyl]-1 H-pyrrole-1 ,2-dicarboxylate (300 g, 0.69 mol) and K2CO3 (170 g, 1.23 mol) in MeOH (2500 mL) is stirred for -12 hour at ambient temperature. The reaction mixture is filtered, and the solid is washed with EtOAc (2 X 100mL). The combined organic washings are then treated with H O (1 X 1000 mL), saturated NaCl solution (2 X lOOOmL), dried over MgSθ4 and concentrated in vacuo. The resulting material is chromatographed (EtOAc:hexane, 1 :3) to give methyl 3-amino-4-[1-(2-fluorophenyl)-2(R)-[(tetrahydropyran-2- yloxy)ethyl]-1 H-pyrrole-2-carboxylate. To a 0°C solution of methyl 3-amino-4-[1 -(2-fluorophenyl)-2(R)-[(tetrahydropyran-2-yloxy)ethyl]- 1 H-pyrrole-2-carboxylate (150 g, 0.41 mol) in CH2CI2 (1300 mL) is added a solution of benzoyl isothiocyanate (150 g, 0.92 mol) in CH2CI2 (200 mL) . The reaction mixture is allowed to warm to ambient temperature and is stirred for -12 hours. The solvent is removed in vacuo and the residue chromatographed (EtOAc:hexane, 1 :2) to provide methyl 3- [benzoyl[amino(thioxomethylamino)]]-4-[1 -(2-fluorophenyl)-2(R)-[(tetrahydropyran-2- yloxy)ethyl]-1 H-pyrrole-2-carboxylate as an oil. To a 0°C solution of methyl 3-[benzoyl[amino(thioxomethylamino)]]-4-[1 -(2-fluorophenyl)-2(R)- [{(tetrahydropyran-2-yl}oxy)ethyl]-1 H-pyrrole-2-carboxyiate (180 g, 0.35 mol) in CH2CI2 (3000 mL) is added Mel (100 g, 0.70 mol, 2 eq) and a solution of DBN (100 g, 0.80 mol, 2.3 eq) in CH2CI2 (500 mL). The mixture is stirred at 0°C for 1 hour and then allowed to warm to ambient temperature. After an additional hour the solvent is removed in vacuo, and the residue chromatographed (EtOAc : hexane, 1 :3) to provide methyl 3-[(benzoylamino) (methylthio)methyleneimino]-4-[1 -(2-fluorophenyl)-2(R)- [(tetrahydropyran-2-yloxy)ethyl]-1 H- pyrrole-2-carboxylate. Methyl 3-[(benzoylamino) (methylthio)methyleneimino]-4-[1 -(2-f luorophenyl)-2(R)- [(tetrahydropyran-2-yloxy)ethyl]-1 H-pyrrole-2-carboxylate (80 g, 0.148 mol) is dissolved in MeOH (2000 mL) and the resulting solution is placed in a high pressure containment vessel. The vessel is chilled in an ice/MeOH bath and NH3 gas is passed through the reaction mixture for 40 minutes. After this time C^ONa (80 g, 1.48g, 10 eq) is added to the NH3/MeOH solution and the vessel is sealed and heated to 100°C for 10 hours. The reaction mixture is then cooled to ambient temperature and is stirred for - 12 hours. The vessel is cooled to 0°C before being opened, and the reaction mixture is then diluted with H2O (1000 mL), after which the excess ammonia and methanol are removed in vacuo. The resulting solution is extracted with EtOAc (2 x 500 mL), treated with saturated NH4CI (-2000 mL) and once again extracted with EtOAc (2 X 1000 mL). The combined organic layers are washed with water (2 X 500 mL), saturated NaCl solution (2 X 500 mL) and dried over MgSθ4. The solvent is removed in vacuo and the residue chromographed (silica gel, EtOAc:MeOH, 95:5) to obtain 2-amino-7-[1 -(2- fluorophenyl)-2(R)-(tetrahydropyran-2-yloxy)ethyl]-3,5-dihydro-4H-pyrrolo[3,2- d]pyrimidin-4-one. Example 2 Similarly prepared to procedure of example 1 is 2-amino-3,5-dihydro-7-[(2-hydroxy-1 - phenyl)ethyl]-4H-pyrrolo[3,2-d]pyrimidin-4-one, m.p. 163-166°C. The racemic β-(hydroxymethyl)-β-phenyipropionitrile intermediate is prepared as follows: A solution of methyl phenylacetate (200g, 1.33 mol) in THF (300 mL) is added, dropwise, to a -78°C solution of lithium diethylamide (LDA, 1.4 mol) in THF (2500 mL). After addition is complete, a precipitate forms, and additional THF (200 mL) is added. The resulting mixture is vigorously stirred while a solution of bromoacetonitrile (168g, 1.4 mol) in THF (400 mL) is slowly added. After 20 minutes the cooling bath is removed and the reaction mixture is quenched with saturated NH CI solution (500 mL). After allowing the mixture to slowly warm to ambient temperature any solid material is removed by filtration and the solvent is removed in vacuo. The residue is dissolved in Et 2 0 (1000 mL) and diluted with H 2 O (1000 mL). The organic phase is then washed with 0.5N HCI (1 X 1000 mL), saturated NaCl solution (2 X 1000 mL) and concentrated in vacuo. The residue is then vacuum distilled (-1 mm Hg) and the fraction boiling between 125°C and 145°C is collected to give β-(carbomethoxy)-β-phenylpropionitriie which solidifies upon standing. β-(Carbomethoxy)-β-phenylpropionitrile (144g, 0.76 mol) is dissolved in dimethoxyethane (1500 mL) and NaBH 4 (63.5g, 1.67 mol) is cautiously added. The reaction mixture is stirred for 30 minutes and then heated at reflux for 2 hours. After this time the resulting solution is allowed to cool to ambient temperature and is poured onto ice. The mixture is then treated with 2N HCI (1500 mL) and is subsequently diluted with Et 2 0 (1500 mL). The organic phase is washed with H 2 0 (1 X 1000 mL), saturated NaCl solution (2 X 1000 mL), dried over MgSO 4 and concentrated in vacuo to yield β-(hydroxymethyl)-β-phenylpropionitrile. Examples 3-32 The following compounds of Formula I wherein Ar is as defined in the Table below are prepared as described in previous examples from the appropriate corresponding propionitrile derivative. Ar-CH-CH 2 OH Table 1 - as omer monohydrochloride; 4 - as the monohydrochloride Example 33 2-Amino-7-[1-(2-fluorophenyl)-2(R)-(tetrahydropyran-2-yloxy)ethyl]-3,5-dihydro-4H- pyrrolo[3,2-d]pyrimidin-4-one (see example 1 , 5.0 g, 14.1 mmol) is dissolved in CH 2 CI 2 (150 ml) and treated with N,N-dimethylformamide dimethylacetal (50 mL, 376 mmol). The mixture is stirred overnight and then concentrated on a rotovap to give a yellow solid. The solid is dissolved in MeOH (100 ml) and treated with 1 N HCI (50 mL 50 mmol). The reaction is stirred at room temperature for 5 hours and then concentrated on a rotovap to remove MeOH. The remaining aqueous phase is adjusted to pH 7.0 using saturated aqueous NaHC0 3 . A white solid precipitates, is collected by filtration, and then rinsed with Et 2 0. Recrystallization (MeOH/water) provides 2- dimethylformamidino-7-[1-(2-fluorophenyl)-2(R)-(tetrahydropyran-2-yloxy)ethyl]-3,5- dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one as a white solid, m.p. 257-259°C dec. The above compound (1.0 g, 3.1 mmol), 2-methyl-2-methoxypropionic acid (0.4 g, 3.4 mmol), dimethylaminopyridine (188 mg, 1.5 mmol) and 1 -ethyl-3-(3-dimethylamino- propyi)carbodiimide hydrochloride (1.2 g, 6.1 mmol) are combined and dissolved in CH 2 CI 2 (75 ml). The reaction is stirred under an inert atmosphere for 1.5 hours and then transferred to a separatory funnel. The mixture is partitioned between CH CI 2 and water (150 mi). The organic phase is separated, washed with brine (75 ml), dried over MgS0 4 , and then concentrated on a rotovap. Flash chromatography (3 - 6% MeOH/CH 2 CI 2 ) provides the purified N-protected acylation product. The N-protected acylated derivative (800 mg, 1.9 mmol) is dissolved in EtOH (50 ml) and treated with NaBH 4 (200 mg, 5.3 mmol) for 2 hours at room temperature. The EtOH is removed on a rotovap and the residue partitioned between EtOAc (150 ml) and water (150 ml). The organic phase is separated, washed with brine (75 ml), dried over MgS0 4 and concentrated on a rotovap. Flash chromatography (3% MeOH/CH 2 CI 2 ) provides 2- amino-7-[1-(2-fluorophenyl)-2-(R)-(2-methyl-2-methoxypropionyloxy)-ethyI]-3,5-dihydro- 4H-pyrrolo[3,2-d]pyrimidin-4-one as a white solid, m.p. 150-155°C. Example 34 (a) Methyl 3-amino-4-[1 -(2-methoxyphenyl)-2-[(tetrahydropyran-2-yloxy)ethyl]-1 H- pyrrole-2-carboxylate (600mg, 1.6 mmoie), isopropanol (10ml), cyanamide (3g, 71.4 mmole) and concentrated HCI (0.3ml) are placed in a thick walled, sealable glass tube. The tube is sealed with a teflon stopper and heated at 120°C for 8 hours. The system is allowed to cool before being carefully opened, the solvents and other volatile material are removed under reduced pressure. Water (5ml) and ethyl acetate (5 ml) are added and after 1 hour at room temperature a white precipitate forms. This solid is filtered off and identified (by nmr and TLC) as the desired product. The solid is dissolved in methanol and the solution is filtered. The product is crystallized by the addition of ethyl ether, separated by filtration and dried in an oven at 50°C under reduced pressure to give 2-amino-3,5-dihydro-7-[2-hydroxy-1 -(2-methoxyphenyl)ethyl]-4H-pyrrolo[3,2- d]pyrimidin-4-one of Example 9, m.p. 262-265°C. Example 35 Similariy prepared is 2-amino-3,5-dihydro-7-[2-(R)-hydroxy-1-(2-fluorophenyl)ethyl]-4H- pyrrolo[3,2-d]pyrimidin-4-one of example 1 , m.p. 263-264°C. Example 36 Preparation of 1 ,000 capsules each containing 25 mg of the active ingredient, using the following ingredients: Active ingredient 25.00 g Lactose 192.00 g Modified starch 80.00 g Magnesium stearate 3.00 g Procedure: All the powders are passed through a screen with openings of 0.6 mm. Then the drug substance is placed in a suitable mixer and mixed first with the magnesium stearate, then with the lactose and starch until homogeneous. No. 2 hard gelatin capsules are filled with 300 mg of said mixture each, using a capsule filling machine.

Claims: What is claimed is: 1. A compound of the formula Ar-CH-CH 2 OH wherein Ar represents biaryl, carbocyclic or heterocyclic aryl. 2. A compound according to claim 1 having the configuration of the formula 3. A compound according to claim 1 of formula wherein Ri and R 2 represent independently hydrogen, halo, lower alkyl, hydroxy, lower alkoxy, aryl-lower alkoxy, acyloxy, aryloxy, trifluoromethyl, cyano, (hydroxy, lower alkoxy or acyloxy)-lower alkyl, or (lower alkylthio, lower alkylsulfonyl or lower alkylsulfonyl)- lower alkyl; or R^ and R 2 together on adjacent carbon atoms represent lower alkylenedioxy. 4. A compound according to claim 1 or 2 wherein Ar is monocyclic heterocyclic aryl comprising thienyl, furanyl, pyridyl, pyrrolyl, thiazolyl, pyrazinyl, pyridazinyl or pyrazolyl. 5. A compound according to claim 1 or 2 wherein Ar is phenyl, halophenyl or pyridyl. 6. A compound according to claim 1 or 2 wherein Ar is phenyl, chlorophenyl or fluorophenyl. 7. A compound according to claim 1 or 2, which is i) a tautomer of the compound of formula I or la; ii) in the form of a pharmaceutically acceptable prodrug ester, or iii) in the form of a pharmaceutically acceptable salt. 8. A pharmaceutical composition comprising a compound according to claim 1 or 2 in combination with one or more pharmaceutically acceptable carriers. 9. A method (i) of inhibiting purine nucleoside phosphorylase activity in mammals and treating diseases and conditions responsive thereto, e.g. autoimmune disorders, rejection of transplantation, or psoriasis; (ii) of selectively suppressing T-cell function and cellular immunity in mammals; (iii) of inhibiting the phosphoroiysis and metabolic breakdown of antiviral or antitumor purine nucieosides in mammals; or (iv) of potentiating the antiviral or antitumor effect of 2' or 3'-monodeoxypurine nucieosides or of 2', 3'-dideoxypurine nucieosides in mammals, which comprises administering to a mammal in need thereof an effective inhibiting amount of a compound of the invention or of a pharmaceutical composition comprising a said compound in combination with one or more pharmaceutically acceptable carriers, (and if appropriate in conjunction with the purine nucleoside, either separately or in combination therewith). 10 Use of a compound according to claim 1 or 2, for the preparation of a medicament for treatment of diseases and conditions responsive to inhibition of purine nucleoside phosphorylase activity, e.g. for inhibiting transplant reection.

Inventors: MCQUIRE LESLIE WIGHTON, MUGRAGE BENJAMIN BIRO, VAN DUZER JOHN HENRY, MCQUIRE, LESLIE, WIGHTON, MUGRAGE, BENJAMIN, BIRO, VAN DUZER, JOHN, HENRY
Applicants: NOVARTIS AG, NOVARTIS ERFIND VERWALT GMBH, NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH
Application year: 1998
Main classification: C07D487
IPC codes: A61K31, A61P17, A61P31, A61P35, A61P37, A61P43, C07D487